US FDA adds new warnings on statins, but routine liver tests dropped
This article was originally published in Scrip
Executive Summary
The US FDA on 28 February had some good and bad news about cholesterol-lowering agents, commonly known as statins, such as Pfizer's Lipitor (atorvastatin), Merck's Mevacor (lovastatin) and AstraZeneca's Crestor (rosuvastatin).